A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

NCT06116136 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

MSI-H/dMMR Gastroesophageal-junction Cancer
MSI-H/dMMR Gastric Cancer

Interventions

DRUG: S095029
DRUG: pembrolizumab 200 mg (KEYTRUDA ®)

Sponsor

Servier Bio-Innovation LLC

Collaborators

[object Object]
[object Object]